Literature DB >> 11476902

Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer.

E Ferriès1, F Connan, F Pagès, J Gaston, A M Hagnéré, A Vieillefond, N Thiounn, J Guillet, J Choppin.   

Abstract

In many types of cancer, p53 frequently accumulates in tumor cells and anti-p53 antibodies can be detected. However, only four CD8(+) T-cell epitopes from p53 have been identified in humans so far. To further analyze the development of a T-cell response against p53, peptides having binding motifs specific for HLA-A1, -A2, -A3, -A24, -B7, -B35, -B44, and -B51 molecules have been defined. The HLA-binding capacity of those peptides was tested, and the stability of formed complexes was defined. Thirteen peptides that bound to HLA-A24 and -B44 molecules are presented. The positive peptides were then used to detect the anti-p53 response of CD8(+) T lymphocytes from patients with bladder cancer. Six peptides, presented by HLA-A2, -B51, or -A24, were able to stimulate T cells from two patients (among 16) with tumor cells that strongly accumulated p53. On the contrary, p53 peptides systematically failed to stimulate T cells from healthy donors or patients with low or undetectable levels of p53 in their tumor cells. These results have led to the identification of four new potential T CD8(+) epitopes from p53: 194-203 associating with HLA-B51 and 204-212, 211-218, and 235-243 associating with HLA-A24.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476902     DOI: 10.1016/s0198-8859(01)00266-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.

Authors:  S Justesen; S Buus; M H Claesson; A E Pedersen
Journal:  Immunology       Date:  2007-07-04       Impact factor: 7.397

2.  Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.

Authors:  Hua-Wen Sun; Qi-Bing Tang; Yong-Jun Cheng; Sheng-Qian Zou
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

3.  Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.

Authors:  Koichi Sakakura; Kazuaki Chikamatsu; Nobuhiko Furuya; Ettore Appella; Theresa L Whiteside; Albert B Deleo
Journal:  Clin Immunol       Date:  2007-07-12       Impact factor: 3.969

4.  Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.

Authors:  Takemasa Tsuji; Junko Matsuzaki; Erika Ritter; Anthony Miliotto; Gerd Ritter; Kunle Odunsi; Lloyd J Old; Sacha Gnjatic
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

5.  HLA Class I Allele Frequencies in Southern Iranian Women with Breast Cancer.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Iran J Basic Med Sci       Date:  2013-02       Impact factor: 2.699

Review 6.  The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.

Authors:  A P B Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.